Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

Zacks Bull and Bear of the Day Highlights: Mueller, Cirrus Logic, Nektar Therapeutics, Novartis and Cubist Pharmaceuticals

PR Newswire June 6, 2013

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting

PR Newswire June 3, 2013

Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting

PR Newswire June 1, 2013

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City

PR Newswire May 30, 2013

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

PR Newswire May 16, 2013

Nektar Therapeutics Reports Financial Results for the First Quarter of 2013

PR Newswire May 9, 2013

Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets

PR Newswire May 2, 2013

Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia

PR Newswire April 16, 2013

Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013

PR Newswire April 7, 2013

New Programs Designed to Speed up Approval Process a Key Factor in Biotech Industry's Growth in 2012

Marketwired March 19, 2013

Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston

PR Newswire March 1, 2013

Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results

PR Newswire February 28, 2013

AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation

PR Newswire February 26, 2013

Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets

PR Newswire February 13, 2013

Number of FDA Drug Approvals Reach a 15-Year High in 2012

Marketwired February 7, 2013

Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC)

PR Newswire February 5, 2013

The Real Story Behind AMBS, ARNA, NKTR and URS

Marketwired January 23, 2013

Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013

Marketwired January 16, 2013

Our Pros Knew HMSY, NKTR, TTM and HSP Would Be Top Gainers on Wednesday

Marketwired January 10, 2013

The Real Story Behind NUVA, NKTR, HOLX and VOLC

Marketwired January 10, 2013